{
  "source": "GSE169246",
  "reference": "Zhang et al. Cancer Cell 2021",
  "pmid": "34653365",
  "cancer_type": "TNBC",
  "treatment": "paclitaxel ± atezolizumab",
  "total_pre": 177896,
  "total_post": 164263,
  "pre_proportions": {
    "Tumor": 0.0109,
    "CD8_T": 0.2139,
    "Treg": 0.0631,
    "Macrophage": 0.1463,
    "NK": 0.3326,
    "B_cell": 0.2332
  },
  "post_proportions": {
    "Tumor": 0.0127,
    "CD8_T": 0.207,
    "Treg": 0.0549,
    "Macrophage": 0.1356,
    "NK": 0.4259,
    "B_cell": 0.1638
  },
  "changes": {
    "Tumor": {
      "pre_proportion": 0.0109,
      "post_proportion": 0.0127,
      "delta": 0.0018,
      "fold_change": 1.1651,
      "direction": "increase"
    },
    "CD8_T": {
      "pre_proportion": 0.2139,
      "post_proportion": 0.207,
      "delta": -0.0069,
      "fold_change": 0.9677,
      "direction": "decrease"
    },
    "Treg": {
      "pre_proportion": 0.0631,
      "post_proportion": 0.0549,
      "delta": -0.0082,
      "fold_change": 0.87,
      "direction": "decrease"
    },
    "Macrophage": {
      "pre_proportion": 0.1463,
      "post_proportion": 0.1356,
      "delta": -0.0107,
      "fold_change": 0.9269,
      "direction": "decrease"
    },
    "NK": {
      "pre_proportion": 0.3326,
      "post_proportion": 0.4259,
      "delta": 0.0933,
      "fold_change": 1.2805,
      "direction": "increase"
    },
    "B_cell": {
      "pre_proportion": 0.2332,
      "post_proportion": 0.1638,
      "delta": -0.0694,
      "fold_change": 0.7024,
      "direction": "decrease"
    }
  },
  "interpretation": {
    "treatment": "paclitaxel ± atezolizumab (anti-PD-L1)",
    "key_findings": [
      "NK cells expand significantly post-treatment (largest increase)",
      "B cells decrease substantially (largest decrease)",
      "Treg cells decrease (immunosuppression reduced)",
      "Macrophages decrease moderately",
      "CD8_T cells decrease slightly (paclitaxel damages tumor-reactive T cells, per Zhang et al.)",
      "Tumor proportion increases slightly (but absolute numbers may differ)"
    ],
    "kb2_implications": {
      "atezolizumab": {
        "NK_activation_boost": "Strong — NK expansion is the dominant immune response",
        "Treg_suppression": "Moderate — Treg proportion drops ~20%",
        "B_cell_reduction": "Unexpected — B cells drop significantly, possibly paclitaxel effect",
        "CD8_T_damage": "Mild — paclitaxel selectively damages tumor-reactive T cells"
      }
    }
  },
  "kb2_calibration": {
    "cancer_id": "TNBC",
    "drug": "atezolizumab_paclitaxel",
    "source": "GSE169246",
    "reference": "Zhang et al. Cancer Cell 2021",
    "pmid": "34653365",
    "treatment_steps": 10,
    "cell_effects": {
      "Tumor": {
        "proportion_change_rate": 0.00018,
        "direction": "increase",
        "fold_change": 1.1651
      },
      "CD8_T": {
        "proportion_change_rate": -0.00069,
        "direction": "decrease",
        "fold_change": 0.9677
      },
      "Treg": {
        "proportion_change_rate": -0.00082,
        "direction": "decrease",
        "fold_change": 0.87
      },
      "Macrophage": {
        "proportion_change_rate": -0.00107,
        "direction": "decrease",
        "fold_change": 0.9269
      },
      "NK": {
        "proportion_change_rate": 0.00933,
        "direction": "increase",
        "fold_change": 1.2805
      },
      "B_cell": {
        "proportion_change_rate": -0.00694,
        "direction": "decrease",
        "fold_change": 0.7024
      }
    }
  }
}